These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23621549)

  • 21. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
    Martin MG; Vij R
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):320-3. PubMed ID: 19717384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neutrophilic dermatosis of the hands].
    Brajon D; Cuny JF; Barbaud A; Schmutz JL
    Ann Dermatol Venereol; 2011 Oct; 138(10):673-6. PubMed ID: 21978504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of thalidomide in multiple myeloma.
    Schwab C; Jagannath S
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):26-9. PubMed ID: 16879766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebral venous thrombosis in an individual with multiple myeloma treated with lenalidomide.
    Eudo C; Petit A; Mondon K; Rippault H; Dardaine V; Constans T; Hommet C; Cottier JP
    J Am Geriatr Soc; 2011 Dec; 59(12):2371-2. PubMed ID: 22188080
    [No Abstract]   [Full Text] [Related]  

  • 25. The relationship between neutrophilic dermatosis of the dorsal hands and sweet syndrome: report of 9 cases and comparison to atypical pyoderma gangrenosum.
    Walling HW; Snipes CJ; Gerami P; Piette WW
    Arch Dermatol; 2006 Jan; 142(1):57-63. PubMed ID: 16415387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
    Seki JT; Banglawala S; Lentz EM; Reece DE
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
    [No Abstract]   [Full Text] [Related]  

  • 27. Linear IgA bullous dermatosis following influenza vaccination.
    Alberta-Wszolek L; Mousette AM; Mahalingam M; Levin NA
    Dermatol Online J; 2009 Nov; 15(11):3. PubMed ID: 19951639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of treatment-related adverse events in patients with multiple myeloma.
    Mateos MV
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thalidomide-induced severe hepatotoxicity.
    Dabak V; Kuriakose P
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):583-5. PubMed ID: 19083237
    [No Abstract]   [Full Text] [Related]  

  • 30. Neutrophilic dermatosis of the dorsal hands in a farmer.
    Aydin F; Senturk N; Yildiz L; Canturk M; Turanli A
    J Eur Acad Dermatol Venereol; 2004 Nov; 18(6):716-7. PubMed ID: 15482306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
    Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
    J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intra-epidermal neutrophilic IgA dermatosis associated with IgA myeloma].
    Bernard P; Amici JM; Bedane C; Catanzano G; Bonnetblanc JM
    Ann Dermatol Venereol; 1990; 117(11):890-2. PubMed ID: 2129185
    [No Abstract]   [Full Text] [Related]  

  • 33. Lenalidomide, a thalidomide derivative, shows promise in various applications.
    Oestreicher P
    ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
    [No Abstract]   [Full Text] [Related]  

  • 34. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis.
    Kagoya Y; Nannya Y; Kurokawa M
    Leuk Res; 2012 Aug; 36(8):1016-21. PubMed ID: 22579366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
    Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M; Jakubowiak A; Mehta J; Niesvizky R; Orlowski R; Siegel D; Singhal S; Vescio R; Wang M; Zangari M; Munshi NC
    Clin Adv Hematol Oncol; 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PubMed ID: 18000495
    [No Abstract]   [Full Text] [Related]  

  • 36. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
    Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
    Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of thalidomide in the treatment of multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of bullous contact dermatitis caused by butifos].
    Karimov AM; Inagamova DA; Iusupov BIu
    Gig Tr Prof Zabol; 1988 Nov; (11):57. PubMed ID: 2976716
    [No Abstract]   [Full Text] [Related]  

  • 39. Thalidomide in the treatment of multiple myeloma.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reducing neurotoxicity in the management of multiple myeloma.
    Gertz MA
    Leuk Lymphoma; 2011 Nov; 52(11):2043-4. PubMed ID: 21740295
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.